Novo Nordisk’s fast-acting mealtime insulin approved in the US
The US Food and Drug Agency (FDA) has given the go-ahead for marketing of a new fast-acting mealtime insulin from the Danish drug group Novo Nordisk.
BY ALBERT RØNNING-ANDERSSON
FDA has approved Novo Nordisk’s new fast-acting mealtime insulin Fiasp for the treatment of adults with diabetes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo resubmits Fiasp application in the US
For abonnenter
Novo Nordisk launches new insulin in first countries
For abonnenter
New Novo Insulin recommended for EU approval
For abonnenter
